Delivery Order SPE2DB24D2216-SPE2DB25FGPPD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $5,051.16. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion by August 6, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a ceiling value of $4,284.71. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025. The award was competitively procured with no set-aside designation, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,918.73. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,467.94 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitive award, structured as a firm fixed-price delivery order with no set-aside designation, is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,134.31 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) under a firm fixed-price contract. The award was made on August 12, 2025, with an ultimate completion date of August 13, 2025. This delivery order represents a non-set-aside competitive award to support federal medical procurement needs, with performance to be executed at the contractor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 30 mg capsules (100-count) with a contract value of $2,117.56 and completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) under a firm fixed-price contract valued at $2,196.14. This is a non-set-aside award, indicating competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order is issued against...
- The Defense Logistics Agency awarded a $3,140.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100 count) on August 15, 2025, with an ultimate completion date of August 18, 2025. The contract, which carries no set-aside designation, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPPDDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that supplies critical medical commodities to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains, ranging from specialty medications and vaccines to brand-name and generic drugs. This particular delivery order for Vyvanse, a controlled stimulant medication used in treating attention-deficit/hyperactivity disorder, reflects AmerisourceBergen's ongoing role as a key vendor supporting military medical supply chains through DLA's pharmaceutical procurement initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/18/25 |